Share price · ENLV
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ENLV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026-20.8%
- 30 Oct 2026-29.9%
Nothing announced by ENLV that day or the session before.
- 30 Jul 2026-13.3%
- 28 Jul 2026-47.4%
- 16 Jul 2026-18.7%
Nothing announced by ENLV that day or the session before.
- 14 Jul 2026-9.3%
- 27 May 2026+14.3%
- 13 Apr 2026-12.8%
Nothing announced by ENLV that day or the session before.
- 8 Apr 2026+12.0%
- 30 Mar 2026-14.3%
Nothing announced by ENLV that day or the session before.
Share of unusual movement by asset
For each asset, the share of ENLV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Allocetraevents and moves
| 4 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 7% |
| Other company news (earnings, financing, releases naming no asset) | — | 41% |
| Sessions with no dated event | — | 52% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Macrophage reprogrammingCell therapy | Osteoarthritis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | — | $2.1M | $2.4M+ <$0.1M short-term inv. | $1.9M | report ↗ |
For the period ended June 30, 2025, Enlivex Therapeutics reported no disclosed revenue. R&D spend was $2.14M, up 7% YoY from $2M, while cash and equivalents stood at $2.35M. The company reported a net loss of $1.87M, corresponding to a quarterly net burn of $1.87M.
The accompanying proxy materials disclose an annual general meeting scheduled for November 10, 2025, with proposals to elect five directors, increase authorized share capital from NIS 18,000,000 divided into 45,000,000 ordinary shares to NIS 200,000,000 divided into 500,000,000 ordinary shares, and reappoint Yarel & Partners as independent registered public accountants. Management will also review the audited consolidated financial statements for the year ended December 31, 2024 at the meeting.
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q2 | — | $2.0M | $4.2M+ $0.2M short-term inv. | $3.1M | report ↗ |
| 2023-Q2 | — | $5.0M | $3.9M+ $25M short-term inv. | $6.8M | report ↗ |
| 2022-Q2 | — | $4.1M | $21M | $9.9M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $9.2M | $2.4M+ $3.9M short-term inv. | —-$10M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $11M | $3.7M+ $0.2M short-term inv. | $3.8M-$13M operating cash flow | report ↗ |
| 2023-FY | — | $19M | $1.2M+ $5.1M short-term inv. | $7.3M-$24M operating cash flow | report ↗ |
| 2022-FY | — | $19M | $50M+ $0.3M short-term inv. | $7.8M-$24M operating cash flow | report ↗ |
| 2021-FY | — | $13M | $12M+ $63M short-term inv. | $3.6M-$18M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
No Form 4 transactions on file in the stored window.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 35 reporting institutions held 3.6M shares ($3.3M, 21.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Diametric Capital, LP | 1,483,178 | $1.4M |
| 2 | ARK Investment Management LLC | 628,310 | $584K |
| 3 | PRELUDE CAPITAL MANAGEMENT, LLC | 225,738 | $210K |
| 4 | TWO SIGMA INVESTMENTS, LP | 146,412 | $136K |
| 5 | UBS Group AG | 138,328 | $129K |
| 6 | BANK OF AMERICA CORP /DE/ | 130,401 | $121K |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 128,192 | $119K |
| 8 | JPMORGAN CHASE & CO | 125,948 | $113K |
| 9 | GOLDMAN SACHS GROUP INC | 102,093 | $95K |
| 10 | XTX Topco Ltd | 100,362 | $93K |
| 11 | MORGAN STANLEY | 98,333 | $91K |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 80,560 | $75K |
| 13 | Invesco Ltd. | 61,654 | $57K |
| 14 | CITADEL ADVISORS LLC | 27,965 | $26K |
| 15 | TWO SIGMA SECURITIES, LLC | 20,044 | $19K |